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A B S T R A C T
Background: In Japan, intravenous digoxin was previously recommended as a standard drug for acute
control of the heart rate in atrial ﬁbrillation (AF)/atrial ﬂutter (AFL) patients with chronic heart failure
(CHF). Treatment alternatives for such cases were limited and new drugs for this purpose are needed. In
November 2013, landiolol hydrochloride (Onoact1 50 for Injection, Ono Pharamaceutical, Osaka, Japan)
was approved with the indication for ‘‘tachyarrhythmia (AF/AFL) in patients with cardiac dysfunction.’’
However, clinical experience with this condition is still insufﬁcient. Therefore, it is important to conduct
a surveillance of landiolol under actual clinical settings. In addition, collecting data on the mid- and long-
term outcomes in patients treated with landiolol which have not been collected in clinical trials are
indispensable.
Methods: This prospective survey will involve patients treated with landiolol for the treatment of
tachyarrhythmia (AF/AFL) in cardiac dysfunction at Japanese medical facilities from June 2014 to May
2017. The planned number of patients for analysis is approximately 500. The evaluations will be made
not only to identify the adverse events and clinical effectiveness of the drug, but also to characterize the
mid- and long-term outcomes of patients receiving and switching to oral-b-blockers after the
discontinuation of landiolol.
Results: This study was started in June 2014 (registration period 2 years, survey period 3 years) and will
end in May 2017.
Conclusions: This survey will clarify both the characteristics and mid- and long-term outcome of using
landiolol to treat AF/AFL patients with cardiac dysfunction in clinical practice. Moreover, this survey will
simultaneously provide important data that will reveal the possible gap between clinical trials and
clinical practice in these patients.
 2014 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.
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Atrial ﬁbrillation (AF) is an arrhythmia that often develops in
the presence of heart failure (HF) [1,2]. The presence of AF reduces
cardiac output by about 15–25% and possibly results in a
deterioration of the hemodynamics in HF patients [3]. Furthermore,
the excessive ventricular rate, loss of atrial contraction, and
irregular ventricular ﬁlling time that is associated with AF may all
cause negative clinical outcomes in patients with HF [4–10].* Corresponding author at: 8-2, Kyutaromachi 1-Chome, Chuo-ku, Osaka-shi
541-8564, Japan. Tel.: +81 6 6263 2948; fax: +81 6 6263 2969.
E-mail address: mas.matsushita@ono.co.jp (M. Matsushita).
http://dx.doi.org/10.1016/j.jjcc.2014.09.008
0914-5087/ 2014 Japanese College of Cardiology. Published by Elsevier Ltd. All rightsDrug treatment of AF and atrial ﬂutter (AFL) entails a rhythm
control and a rate control. Rhythm control is typically achieved
with the administration of Na channel blockers and K channel
blockers, either alone or in combination based on the patient
characteristics [2,11]. Rate control has been primarily regulated
with the administration of b-blockers, Ca channel blockers, and
digoxin, again either alone or in combination. Before selecting a
drug for rate control it is necessary to consider the presence/
absence of other complications, such as Wolff–Parkinson–White
syndrome, left ventricular dysfunction, and obstructive pulmonary
disease; Ca channel blockers and b-blockers have negative
inotropic actions while digoxin does not. Therefore, digoxin has
conventionally been recommended the most effective drug for rate
control in AF/AFL patients with cardiac dysfunction. In addition, it
is recommended to follow-up digoxin treatment with low doses of reserved.
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currently no consensus for the proper methods for using oral
b-blockers in AF/AFL patients with HF and treatment with these
drugs has only been done empirically.
Landiolol is a short-acting b-blocker that is rapidly metabolized
to inactive forms in the blood and liver, resulting in a half-life of
approximately 4 min in the human blood. In addition, it selectively
binds to b1 receptors, with a b1 receptor selectivity ratio (b1/b2)
as high as 251. Furthermore, landiolol rapidly reduces heart late
(HR) without lowering blood pressure [12]. Based on these
properties, landiolol has been reported to be useful for treating
several acute disorders. A clinical study (J-Land Study) was carried
out in order to evaluate the efﬁcacy and safety of landiolol in
comparison to digoxin in AF/AFL patients with a New York Heart
Association class III–IV, a left ventricular ejection fraction (LVEF) of
25–50%, and a HR 120 bpm or higher [13]. On the basis of the
results, in 2013, landiolol was approved for ‘‘tachyarrhythmia
(AF/AFL) in patients with cardiac dysfunction’’.
Therefore, in the current ‘‘AF Treatment Guidelines’’ (revised
edition, 2013) landiolol is recommended as the rate control
treatment drug for use in AF patients with HF (Class I, Level B)
[14]. However, a sufﬁcient evaluation of the safety and efﬁcacy of
landiolol during clinical use has not been performed. Moreover, no
information about mid- and long-term outcome is available and
information about switching to oral b-blockers from landiolol is
also not sufﬁcient.
Under such circumstances, it is mandatory to continue
collecting data on landiolol treatment in AF/AFL patients with
cardiac dysfunction especially in view of the anticipated increase
of these patients in our aging society. To achieve these goals, we
propose the design and details of the present study in this report.
Methods
Patients
The target patients for this study will be AF/AFL patients with
cardiac dysfunction. Because this study is performed under clinical
settings, no special exclusion criteria will be applied for the
selection of patients. The number of patients feasible to enroll and
that enables a comparison analysis with the results from the
domestic clinical trials is established as 500 patients and it was
obtained by using an interval estimation of population ratio.
Further, the planned number of patients for this study was
established as 800 patients by taking into consideration possible
occurrences of patient dropout and exclusion from analysis.
Patients’ informed consent will not be obtained because this
study is a survey conducted under the Re-examination system in
compliance with Good Post-marketing Study Practice ordinance
under the Japanese Pharmaceutical Affairs Act.
Research facilities
In view of the purpose of this study, this study will be
performed in hospitals with sufﬁcient experience in HF treatment;
the target numbers of patients for this study is 800; namely, 5–10
patients per medical institution (hospital department) in a total of
80–160 medical institutions.
Design
This study will be carried out continuously with the use of an
electronic data capture (EDC) system; the ADDIN System (ASKLEP
Inc., Tokyo, Japan) will be employed as an EDC system, with the
electronic signature serving as the physician’s signature. Baseline
data will be collected from the admission episodes between June2014 and May 2016 (plan) while outcome data will be collected
until 180 days after the start of treatment with landiolol.
Objectives
The objectives of the present study are to identify:
1) Patient characteristics that required landiolol to control the
conditions with rapid AF/AFL with cardiac dysfunction.
2) Status (frequency, type, severity, etc.) of adverse drug reactions
(adverse events) associated with the negative inotropic effects
of landiolol.
3) Status of concomitant medication and interactions with drugs
acting on the circulation, among others.
4) Landiolol dosage and its effects on heart rate and blood pressure
(BP) during the treatment.
5) Dose, presence/absence of oral b-blocker after discontinuation
of landiolol, and dose of oral b-blockers.
6) Death and readmission due to HF during the 180-day period
after the start of treatment with landiolol.
Data collection/processing (attachments)
Data will be entered with the web-based EDC system. For each
patient, the following baseline data will be collected: demographic
characteristics, complications, HR, BP, cardiac function, and
electrocardiographic (ECG) ﬁndings. The condition of all patients
will be investigated from the start of treatment with landiolol to
7 days after discontinuation of its use and will cover the following
information: status of treatment with landiolol, status of switching
to oral b-blockers, HR, BP, cardiac function, ECG ﬁndings, and any
status related to adverse events. In addition, information on the
survival of individual patients will be collected for investigation of
outcome until 180 days after the start of treatment with landiolol.
Conﬁdentiality of patients
The conﬁdentiality of individual patients will be protected in
this study because it is not designed to collect information about
direct identiﬁers (name, address, telephone number, etc.). Access
to the EDC system from each hospital is carefully managed by the
system administrator of the system vendor. The study is performed
in compliance with Good Post-marketing Study Practice, an
ordinance issued by the Ministry of Health Labor and Welfare
establishing the standards for implementation of post-marketing
surveillance of all new drugs approved in Japan.
Statistical analysis
Frequency distribution, summary statistics, etc. will be
calculated concerning background variables, safety endpoints,
and effectiveness endpoints. For the subgroup analysis of adverse
drug reactions, the incidence and 95% conﬁdence interval
(Clopper–Pearson method) will be calculated for each category.
Regarding death and readmission due to HF, independent
determinants will be analyzed in an explorative manner by
multivariate analysis. Furthermore, we will utilize the SAS
program (latest version; Carey, NC, USA) for all statistical analysis
related to this study.
Results planning
This study was started in June 2014 (registration period 2 years,
survey period 3 years) and will end in May 2017.
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This study is a post-marketing surveillance of landiolol
regarding its indication ‘‘tachyarrhythmia (AF/AFL) in patients
with cardiac dysfunction.’’ It is aimed at collecting information to
facilitate the proper use of landiolol by analyzing the background
variables of patients treated with landiolol (demographic data,
disease history, reasons for discontinuation, presence/absence of
re-use, etc.), clinical course (particularly HR, BP, ECG, etc.), and
previously unknown/known adverse events.
However, the information expected from this study is not
conﬁned to this range. Because no clinical report is available
concerning the long-term outcome of AF/AFL patients with HF who
require treatment with landiolol, this study is expected to provide
basic data on these patients in Japan. Conditions necessitating
intravenous b-blockers for HR control associated with AF/AFL
patients in HF can be easily assessed clinically as a single category
and stratiﬁcation of these patients can be enabled. The exploration
of factors determining the outcome in these patients is important.
In fact, the J-Land Study is currently the only paper that has been
published on switching landiolol to oral b-blockers during
treatment [13]. In this study, approximately 80% of the patients
began to receive oral b-blockers following the end of treatment
with landiolol while bisoprolol (1.8  1.3 mg/dose) was used in
about 50% of these cases and carvedilol (3.2  2.7 mg/dose) in about
30%. However, this report did not include a detailed discussion
entailing the initial dose of the oral b-blockers. Although it may be
explorative, and such information will provide useful information
for clinical practice.
Limitations
Two signiﬁcant limitations in the design of this study need to be
discussed. First, it was designed as an observational study without
incorporating a control group. Second, it is a study that will be
accomplished under clinical settings and thus it will be unable to
control all of the variables surveyed, including factors that will
possibly affect the outcome.
Conclusions
In this report, we propose a study designed to collect and supply
information that will facilitate the proper use of landiolol
hydrochloride, a short-acting b1 selective blocker, in the clinical
treatment of ‘‘tachyarrhythmia (AF/AFL) in patients with cardiac
dysfunction’’. The study is expected to provide valuable informa-
tion not only concerning patients for whom landiolol is indicated
and the status of use of landiolol in these patients, but also
concerning the long-term outcome of patient groups and the status
of switching from landiolol to oral b-blockers. This information
will be critical for assessing the clinical signiﬁcance of therapeutic
intervention of this disease with the use of landiolol.
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1. Background
 Demographic data
Sex
Age or date of birth (month/year)
Body weight
Hyperreactivity to drugs
Information speciﬁc to females (pregnancy/lactation)
 Clinical data (medical history)
Date and time of tachyarrhythmia outbreak requiring
treatment with landiolol
Reason for treatment with landiolol
Complications and medical history (especially heart
disease)
Implantable pacemaker
Implantable deﬁbrillator
Respirator use
 Assessment of cardiac function
New York Heart Association (NYHA) classiﬁcation
Electrocardiogram (ECG)
Chest X-ray
Echocardiography
Percutaneous arterial oxygen saturation
Brain natriuretic peptide
2. Treatment with landiolol (start of treatment until 7 days after
discontinuation)
 Route of administration
 Time of administration (start; discontinuation)
 Infusion rate at the start of treatment
 Presence/absence of a temporary suspension and resumption
of treatment
If ‘‘present’’, the date/time of suspension, reason for
suspension, date/time of resumption, and infusion rate at
the time of resumption
 Minimum and maximum infusion rate of landiolol
 Reason for discontinuation
 Presence/absence of re-treatment* (discontinuation of treat-
ment until 7 days after discontinuation)
If ‘‘present’’, the reason for re-treatment and the period of
re-treatment
*: ‘‘Re-treatment’’ indicates a case where treatment with
landiolol is resumed within 7 days after Day 0 (the day when
the therapeutic interventions with landiolol have been
discontinued)
3. Clinical data (start of treatment with landiolol until 7 days after
discontinuation)
 Heart rate (HR) and blood pressure (BP) (immediately before
the start of treatment, immediately after discontinuation,
30 min after discontinuation, and 7 days after discontinua-
tion)
 Presence/absence of ECG
If ECG is ‘‘present’’, a description is made about the
presence/absence of noteworthy changes in the ECG ﬁndings
during treatment with landiolol and the presence/absence of a
sinus rhythm (if sinus rhythm has been restored, the date/time
of ﬁrst restoration to be entered)
 Presence/absence of a stay in the intensive care unit or
coronary care unit for left ventricular dysfunction requiring
treatment with landiolol
If ‘‘present’’, the duration of stay
4. Concomitant drugs/therapies (start of treatment with landiolol
until 7 days after discontinuation)
 Treatment with oral b-blockers
Presence/absence of treatment with such drugs used
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duration with treatment, and daily dose level
HR and BP immediately before start of treatment with such
drugs
 Treatment with other drugs
Presence/absence of treatment with other drugs
If ‘‘present,’’ brand name of the drug, formulation, reason
for treatment, and duration with treatment
 Concomitant therapies
Presence/absence of treatment with concomitant therapies
If ‘‘present,’’ name of the therapy (electrical deﬁbrillation,
pacing, catheter ablation, etc.), frequency of the therapy,
time of the therapy, and reason for treatment
5. Adverse events (immediately after start of treatment with
landiolol until 48 h after discontinuation)
 Presence/absence of adverse events
If ‘‘present,’’ the name of the event, date of outbreak,
seriousness, therapeutic intervention into the event, causal
relationship, other factors involved, dechallenge, rechallenge,
date of outcome assessment, and outcome of the event
If causal relationship is ruled out, the other responsible
factor
 Laboratory test data related to the adverse events (test name,
date, value, and criterion range at the facility)
 If the physician in charge of the survey becomes aware of an
outbreak of a serious adverse event, he/she is required to enter
the event into the survey data entry page of the electronic data
capture system or to inform the Medical Representative of the
event immediately
6. Regarding the outcome (30, 90, and 180 days after the start of
treatment with landiolol)
(1) Outcome
 Presence/absence of outcome check
 Presence/absence of discharge after the end of treatment
of hospitalization-requiring heart failure episode
If ‘‘present,’’ the date of discharge
 Presence/absence of readmission
If ‘‘present,’’ the date of readmission and the reason
 Survival/death
If ‘‘survival,’’ the date of the conﬁrmed survival
If ‘‘death,’’ the date of death, cause, and causal
relationship with landiolol
If outcome is unknown, the reason for why it is
unknown
(2) Heart function test
 NYHA class and date of diagnosis
(3) Impression about the inﬂuence of acute stage heart rate
control with landiolol on long-term heart failure events
 Impression about the inﬂuence of acute stage heart rate
control with landiolol on long-term heart failure events
‘‘No inﬂuence,’’ ‘‘inﬂuence present,’’ ‘‘neutral’’
If ‘‘inﬂuence present,’’ specify the inﬂuenceReferences
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